La Jolla Pharmaceutical (United States)
- World rank, all time
- #28,317 of 42,892
- Rank in United States
- #6,077 of 8,685
- Research works
- 150 ▼ 40% vs 2013–17
- Citations
- 3.7k 24.4 per fractional work
- Top-10% rate
- 5.3% record average 16.5%
- Open access
- 29% world 28%
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 23.4×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 23.4×
- Biochemistry, Genetics and Molecular Biology 2.8×
- Medicine 2.4×
- Materials Science 1.6×
- Nursing 1.5×
- Economics, Econometrics and Finance 1.4×
- Business, Management and Accounting 1.3×
- Psychology 0.8×
- Immunology and Microbiology 0.6×
- Engineering 0.5×
- Computer Science 0.3×
- Mathematics 0.3×
- Chemistry 0.3×
- Neuroscience 0.2×
- Physics and Astronomy 0.2×
- Agricultural and Biological Sciences 0.1×
- Social Sciences 0.1×
Who are the top researchers at La Jolla Pharmaceutical (United States)?
Ranked on the composite score, Matthew D. Linnik lead among researchers whose main affiliation is La Jolla Pharmaceutical (United States).
- 1 Matthew D. Linnik United States · #835,522 worldwide 51 citations · 16 works
Which keywords describe research at La Jolla Pharmaceutical (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Glycosylation, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Cancer, Inflammation and Toll-like Receptors.
- Sepsis
- Peptide Synthesis
- Thrombosis
- Glycans
- TGF-ß
- Foxp3
- Drug Delivery
- Angiogenesis
- Autoimmunity
- Gait Speed
- Parkinson's Disease
- Systemic Lupus Erythematosus
- Drug Discovery
- Oxidative Stress
- Occupational Safety
- Elderly
- Epidemiology
- Fc Receptors
- Inflammation
- Monoclonal Antibodies
- Glycosylation
- Therapeutic Antibodies
- Antibody Engineering
- Cancer
- Toll-like Receptors
- Risk Perception
- Safety Culture
- Antiphospholipid Syndrome
- Muscle Strength
- Nanoparticles
- Fall Risk
- Primary Care
- Management
- Healthcare
- Clinical Trials
- Immune System
- Disability
- Mucins
- Foldamers
- Protein-Protein Interactions
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Glycosylation13▲ 38×3 topics
- Monoclonal Antibodies10▲ 46×3 topics
- Therapeutic Antibodies10▲ 51×2 topics
- Inflammation10▲ 2.7×29 topics
- Antibody Engineering10▲ 64×1 topic
- Fc Receptors10▲ 64×1 topic
- Cancer8▲ 4.0×16 topics
- Epidemiology7▲ 1.18×29 topics
- Toll-like Receptors5▲ 21×3 topics
- Elderly5▲ 14×4 topics
- Risk Perception5▲ 18×2 topics
- Occupational Safety5▲ 46×1 topic
- Safety Culture5▲ 54×1 topic
- Oxidative Stress5▲ 1.77×18 topics
- Antiphospholipid Syndrome5▲ 60×1 topic
- Drug Discovery5▲ 7.8×6 topics
- Muscle Strength5▲ 25×2 topics
- Systemic Lupus Erythematosus5▲ 55×1 topic
- Nanoparticles4▲ 2.3×11 topics
- Parkinson's Disease4▲ 13×2 topics
- Fall Risk4▲ 82×1 topic
- Gait Speed4▲ 82×1 topic
- Primary Care4▲ 6.5×6 topics
- Autoimmunity4▲ 12×4 topics
- Management4▲ 3.3×7 topics
- Angiogenesis4▲ 5.9×9 topics
- Healthcare4▲ 3.4×5 topics
- Drug Delivery4▲ 4.9×5 topics
- Clinical Trials3▲ 3.5×10 topics
- Foxp33▲ 27×1 topic
- Immune System3▲ 6.3×3 topics
- TGF-ß3▲ 12×1 topic
- Disability3▲ 19×2 topics
- Glycans3▲ 23×1 topic
- Mucins3▲ 23×1 topic
- Thrombosis3▲ 8.1×5 topics
- Foldamers2▲ 21×1 topic
- Peptide Synthesis2▲ 21×1 topic
- Protein-Protein Interactions2▲ 16×2 topics
- Sepsis2▲ 9.3×3 topics
Which research topics does La Jolla Pharmaceutical (United States) publish most on?
By volume in 2022–2025: Monoclonal and Polyclonal Antibodies Research, HER2/EGFR in Cancer Research, Advancements in Transdermal Drug Delivery and Cancer Treatment and Pharmacology.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 2 works
- 2 HER2/EGFR in Cancer Research Oncology 1 works
- 3 Advancements in Transdermal Drug Delivery Pharmaceutical Science 1 works
- 4 Cancer Treatment and Pharmacology Oncology 0 works
- 5 Electrospun Nanofibers in Biomedical Applications Biomaterials 0 works
- 6 Bioinformatics and Genomic Networks Molecular Biology 0 works
- 7 Cardiac Imaging and Diagnostics Radiology, Nuclear Medicine and Imaging 0 works
- 8 Silk-based biomaterials and applications Biomaterials 0 works
- 9 Dyeing and Modifying Textile Fibers Building and Construction 0 works
- 10 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has La Jolla Pharmaceutical (United States)'s research output changed?
Output in 2018–2022 was 40% lower than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in San Diego
- University of California San Diego
- San Diego State University
- Scripps Research Institute
- University of San Diego
- University of California San Diego Medical Center
- General Atomics (United States)
- Scripps Health
- Naval Medical Center San Diego
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.